MoneyWorks4Me

Piramal Pharma informs about disclosure

02 Jun 2025 Evaluate

Piramal Pharma has informed that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of the company’s facility at Aurora, Canada from 26th May 2025 to 30th May, 2025. The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation. The Company remains committed to maintain the highest standards of compliance.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1844.90
Dr. Reddys Labs. 1217.35
Cipla 1391.95
Lupin 2065.00
Zydus Lifesciences 1223.95
View more..